AZD8601 study in CABG patients

Study identifier:D9150C00003

ClinicalTrials.gov identifier:NCT03370887

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized, double-blind, placebo-controlled, multi-centre, sequential design, phase IIa study to evaluate safety and tolerability of epicardial injections of AZD8601 during coronary artery bypass grafting surgery

Medical condition

heart failure

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD8601, Placebo

Sex

All

Actual Enrollment

11

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 05 Feb 2018
Primary Completion Date: 30 Jun 2021
Study Completion Date: 30 Jun 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria